Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05370001
Other study ID # ETT-size Karolina Galmén
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 13, 2022
Est. completion date January 26, 2023

Study information

Verified date May 2022
Source Region Stockholm
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

High Frequency Jet Ventilation (HFJV) can be used in liver tumour ablation to minimise breathing related movements. The jet cannula is placed freely inside an endotracheal tube (ETT) and the outflow of air is passive, moving out in the interspace between the jet cannula and the inner walls of the ETT. This study aims to investigate whether the tube size can influence the washout of carbon dioxide using two different sizes of ETT's.


Description:

The aim of the present prospective randomised study is to compare differences in levels of carbon dioxide between two different endotracheal tube-sizes. Background: High Frequency Jet Ventilation (HFJV) has become an important technique for ventilation during stereotactic near-diaphragm ablation to minimise breathing related movements. Thus, avoiding risks associated to movements and subsequent dislocation of the target tumour. HFJV is being increasingly used during CT-guided, percutaneous liver tumour ablation. As shown previously, breathing related movements in upper abdominal organs, are decreased significantly when compared to conventional ventilation. When HFJV is being used in the setting for tumour ablation the jet cannula is inserted into an ordinary endotracheal tube (ETT). The HFJV catheter is placed in the ETT and is during jet ventilation lying freely within the tube. Right placement is confirmed by a harmonic curve on the screen of the jet ventilator. It is of great importance that the ETT is not obstructed as this type of ventilation is dependent on passive outflow of expired air, through the tube, passing from the lungs around the catheter within the tube into the surrounding air. If the lumen around the catheter within the ETT is becoming too small, there is a risk for intrinsic PEEP built up, and subsequent risk for barotrauma, pneumothorax. The space between the catheter and the inner lumen of the ETT also governs the exhalation of gas, the passage of expired gas containing CO2 from the lung. A small inner diameter of the ETT may thus likewise increase the risk for a raise in arterial carbon dioxide. To minimise these risks, an ETT one size larger than usual can be used to lower the risk for pressure increase and improve gas exchange. One should consider the risks, even though very low, of mechanical injury in the airway when larger ETT's are being used. Previous studies on arterial blood gas in liver tumour was performed using a ETT one size larger (size 9 in men). TadiƩ et al showed that laryngeal injury was related to the length of intubation, the non-use of muscle relaxant drugs and the height/ETT diameter ratio. This was a study made in an ICU and all patients were intubated >24 hrs and therefore not fully applicable to the OR-setting. Jaensson et al describe a significant lower risk for post operative sore throat (POST) using a smaller ETT size in women during elective surgery. Myles et al describe women being 1.5 times more likely to report having POST compared to men. To defend the superiority of a larger tube size further studies assessing the effect of the ETT size on the arterial CO2 tension is needed. Methods: After written, informed consent, 26 (13 in each group) consecutive, male patients planned for liver tumour ablation with HFJV will be included in the study. Participants will be randomized to ETT size 8 or 9. Randomisation will take place in an earlier stage with the help of a computerised randomisation generator where 26 envelopes are prepared in which the information of tube size is to be found. The envelopes are on the outside anonymous. The envelopes will be opened by the anaesthetic nurse in the operation room, who will then prepare the ETT. An arterial line will be placed before the start of anaesthesia and a transcutaneous measuring device will be placed on the forehead of the patient. After preoxygenation, induction and ETT placement, conventional ventilation will be started and a normal tcCO2 value reached (tcCO2 4,5-5 before the start of HFJV). HFJV will have pre-set settings with the same values for all patients. Driving pressure (DP) will be 1,2 bar and frequency 220/min. Measurements from the three different methods; arterial pCO2, transcutaneous CO2 and etCO2 will then be recorded at the start of HFJV (t=0) and then every 15' until t=45 minutes of HFJV. In the case of rapidly increasing CO2, a cut off limit of 10 kPa will be used. When this level is reached, settings on the ventilator will be changed. That means increasing DP and, if needed, lower the frequency. If this does not lead to a satisfactory CO2-level HFJV has to be changed to conventional ventilation until the CO2-level is within normal limits. Any injury during intubation and post extubation stridor (PES) will be recorded. The patient will be asked for post operative sore throat (POST) and any signs of postoperative hoarseness (PH) will be noted in the protocol before leaving the post anaesthetic care unit (PACU) and also approximately 24 hrs after extubation. If symptoms still occur after 24 hrs, follow up will take place approximately 72 hrs and 96 hrs after extubation. If symptoms are still present by this point the patient will be offered a doctor's appointment. Statistics: The power calculation was based on data from previous studies. The base-line PaCO2 among 12 male patients, at the start of HFJV, was 4.9 kPa (SD 0.5) with an increase to mean PaCO2 of 6.7 (SD 1.5) at 15 minutes with HFJV and a tube size of 9. With the hypothesis that the PaCO2 would increase to a mean of 8.0 kPa after 15 minutes of HFJV ventilation, with a tube size 8, groups of 11 patients are needed to verify the difference at a p<0.05 with a power of 80%. To compensate for potential drop-outs, groups of 13 patients is set as the study population. Data will be presented as mean, SD, median and range where applicable. One-way ANOVA will be used on normal distributed data and ANOVA on ranks will be used on non-normal distributed data. Bonferroni's test will be used to compare differences between the different timepoints. A p-value of <0,05 will be considered as statistically significant. Importance of the study: This study is conducted to if the larger endotracheal tube size has benefits in gas exchange when HFJV is being used in liver tumour ablation procedures. Normally it is desirable to use as small ETT as possible as this minimises the risks for airway injury. The risks of air entrapment and even pneumothorax and raise in carbon dioxide levels are also risks that are potentially harmful for the patients and must be avoided. The small risk of using a one size larger ETT would therefore be accepted if the benefits can be shown in this study.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date January 26, 2023
Est. primary completion date January 26, 2023
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male patients scheduled for stereotactic liver tumour ablation. - Need for an arterial line for safe monitoring of hemodynamic and respiratory variables during the procedure/anaesthesia. - Ability to understand the information about the study and be able to leave a written, informed consent. Exclusion Criteria: - Patients with known CO2 retention. - Patients shorter than 160 cm (as an endotracheal tube size 9 would then be too big).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Entotracheal tube size
Compare the levels of carbon dioxide and if it is related to ETT size when using size 9 (routine) or size 8 (intervention).

Locations

Country Name City State
Sweden Danderyd Hospital Stockholm

Sponsors (1)

Lead Sponsor Collaborator
Region Stockholm

Country where clinical trial is conducted

Sweden, 

References & Publications (9)

Biro P, Spahn DR, Pfammatter T. High-frequency jet ventilation for minimizing breathing-related liver motion during percutaneous radiofrequency ablation of multiple hepatic tumours. Br J Anaesth. 2009 May;102(5):650-3. doi: 10.1093/bja/aep051. Epub 2009 Apr 3. — View Citation

Chung DY, Tse DM, Boardman P, Gleeson FV, Little MW, Scott SH, Anderson EM. High-frequency jet ventilation under general anesthesia facilitates CT-guided lung tumor thermal ablation compared with normal respiration under conscious analgesic sedation. J Vasc Interv Radiol. 2014 Sep;25(9):1463-9. doi: 10.1016/j.jvir.2014.02.026. Epub 2014 May 10. — View Citation

Denys A, Lachenal Y, Duran R, Chollet-Rivier M, Bize P. Use of high-frequency jet ventilation for percutaneous tumor ablation. Cardiovasc Intervent Radiol. 2014 Feb;37(1):140-6. doi: 10.1007/s00270-013-0620-4. Epub 2013 May 2. — View Citation

Engstrand J, Toporek G, Harbut P, Jonas E, Nilsson H, Freedman J. Stereotactic CT-Guided Percutaneous Microwave Ablation of Liver Tumors With the Use of High-Frequency Jet Ventilation: An Accuracy and Procedural Safety Study. AJR Am J Roentgenol. 2017 Jan;208(1):193-200. doi: 10.2214/AJR.15.15803. Epub 2016 Oct 20. — View Citation

Galmen K, Harbut P, Freedman J, Jakobsson JG. High frequency jet ventilation for motion management during ablation procedures, a narrative review. Acta Anaesthesiol Scand. 2017 Oct;61(9):1066-1074. doi: 10.1111/aas.12950. Epub 2017 Aug 13. — View Citation

Galmen K, Jakobsson JG, Freedman J, Harbut P. High Frequency Jet Ventilation during stereotactic ablation of liver tumours: an observational study on blood gas analysis as a measure of lung function during general anaesthesia. F1000Res. 2019 Apr 5;8:386. doi: 10.12688/f1000research.18369.1. eCollection 2019. — View Citation

Jaensson M, Olowsson LL, Nilsson U. Endotracheal tube size and sore throat following surgery: a randomized-controlled study. Acta Anaesthesiol Scand. 2010 Feb;54(2):147-53. doi: 10.1111/j.1399-6576.2009.02166.x. Epub 2009 Nov 23. — View Citation

Myles PS, Hunt JO, Moloney JT. Postoperative 'minor' complications. Comparison between men and women. Anaesthesia. 1997 Apr;52(4):300-6. doi: 10.1111/j.1365-2044.1997.89-az0091.x. — View Citation

Tadie JM, Behm E, Lecuyer L, Benhmamed R, Hans S, Brasnu D, Diehl JL, Fagon JY, Guerot E. Post-intubation laryngeal injuries and extubation failure: a fiberoptic endoscopic study. Intensive Care Med. 2010 Jun;36(6):991-8. doi: 10.1007/s00134-010-1847-z. Epub 2010 Mar 18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Carbon dioxide level from an arterial line (PaCO2) after 15 minutes of HFJV. Carbon dioxide level from an arterial line (PaCO2) in kPa will be compared from the levels at baseline to the level at 15 minutes of HFJV. 15 minutes after the start of HFJV
Secondary Dynamics of carbon dioxide during surgery using HFJV The dynamics of carbon dioxide changes obtained from an arterial line (PaCO2) in kPa, transcutaneously (tcCO2) in kPa and end tidal measurement (etCO2) in kPa registered every 15 minutes during the first 45 minutes of HFJV. That is, all values from each timepoint (15 minutes, 30 minutes and 45 minutes after the start of HFJV) will be compared to baseline. From the start of HFJV up until 45 minutes after the start of HFJV
Secondary During HFJV measure pause pressure (PP) and peak pressure . During HFJV measure pause pressure (PP) in mbar and peak pressure in mbar . From the start of HFJV up until 45 minutes after the start of HFJV
Secondary Analysing PaO2 PaO2 in kPa will also be measured and analysed during the procedure. From the start of HFJV up until 45 minutes after the start of HFJV
Secondary Analysing pH pH will also be measured and analysed during the procedure. From the start of HFJV up until 45 minutes after the start of HFJV
Secondary Analysing lactate Lactate in mmol/L will also be measured and analysed during the procedure. From the start of HFJV up until 45 minutes after the start of HFJV
Secondary Analysing saturation Saturation in percent will also be measured and analysed during the procedure. From the start of HFJV up until 45 minutes after the start of HFJV
Secondary Injury of the airway following endotracheal intubation. Signs of apparent mechanical injury in the airway. Signs of apparent injury, being visible injury during intubation and post extubation stridor (PES). Post operative sore throat (POST) and any signs of postoperative hoarseness (PH) At the most 96 hours post extubation.
See also
  Status Clinical Trial Phase
Completed NCT04241887 - Is Thoracic Paravertebral Block a Better Option Than Conscious Sedation for PRFA of Liver Tumors N/A
Recruiting NCT04274868 - Pediatric Hepatic Tumors
Completed NCT02985034 - Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT N/A
Completed NCT02424955 - Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation N/A
Recruiting NCT05555316 - TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma Phase 2
Recruiting NCT03579199 - Practical Application of Indocyanine Green Camera in Laparoscopic Liver Surgery N/A
Completed NCT02958592 - Assessment of Hepatic Fibrosis by Shear Wave Elastography in Patients With Liver Malignancy: A Prospective Single-center Study N/A
Recruiting NCT02203409 - Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy
Enrolling by invitation NCT03739164 - Tampa Associating Microwave Liver Ablation With Portal Vein Ligation for Staged Hepatectomy (TAMLAPS)
Recruiting NCT05211388 - Treat-and-resect Study of Echo Decorrelation Imaging-controlled Radiofrequency Ablation in Liver Tumors N/A
Recruiting NCT05516394 - National Polish Registry of Minimally Invasive Liver Surgery
Completed NCT02849015 - Combination of Cryosurgery and NK Immunotherapy for Tumors in Transplanted Liver Phase 1/Phase 2
Completed NCT02018107 - PET/CT-Assessment of Liver Tumor Ablation N/A
Recruiting NCT01677728 - Effect of Target Therapy on Patients Undergoing Synchronic Hepatectomy for Colorectal Liver Metastases N/A
Recruiting NCT06060899 - Intraoperative Blood Loss Under Standard Versus Low Pneumoperitoneum Pressure During Laparoscopic Liver Resection. N/A
Completed NCT03783871 - NeuWave HCC China Study N/A
Enrolling by invitation NCT01812577 - Paravertebral Block for Percutaneous Radiofrequency Ablation of Liver Lesions
Not yet recruiting NCT05161624 - Accuracy Evaluation of Artificial Intelligence Assisted Liver Tumor Ablation Path Planning
Completed NCT02226666 - Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration N/A
Recruiting NCT04812054 - Dual Hypothermic Oxygenated Machine Perfusion in Liver Transplantation Using Allografts From Donors After Brain Death N/A